What is the role of omalizumab in the treatment of urticaria (hives)?

Updated: Mar 21, 2018
  • Author: Henry K Wong, MD, PhD; Chief Editor: Michael A Kaliner, MD  more...
  • Print

Omalizumab (monoclonal antibody to IgE) is a recombinant biologic molecule effective for chronic urticaria based on two large positive phase III studies and is currently FDA approved for treatment of chronic urticaria. Patients can be treated with 150 or 300 mg subcutaneously every four weeks. [77] The role in acute urticaria has not been determined and further studies are needed. 

Because the use of the aforementioned agents is not widespread, details of dosage and administration are not provided, but references are listed in the bibliography. The use of corticosteroids is more common and is discussed in Medication.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!